Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Progression risk stratification of asymptomatic WM

Romanos Sklavenitis-Pistofidis • 14 Sep 2019
IMW 2019
Rare Diseases Waldenström’s Macroglobulinemia

Romanos Sklavenitis-Pistofidis, MD Dana-Farber Cancer Institute, Boston, MA, gives a brief outline of his work into the progression risk stratification of asymptomatic Waldenstrom macroglobulinemiaspeaking at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Romanos Sklavenitis-Pistofidis

Findings from a sequencing study evaluating tumor & immune cells in pts with MGUS, SMM & myeloma
3:14
Findings from a sequencing study evaluating tumor & immune cells in pts with MGUS, SMM & myeloma
Romanos Sklavenitis-Pistofidis • 13 Mar 2025
Single-cell RNA-sequencing of 6 million tumor and immune cells from patients with MGUS and SMM
4:18
Single-cell RNA-sequencing of 6 million tumor and immune cells from patients with MGUS and SMM
Romanos Sklavenitis-Pistofidis • 7 Dec 2024
A single-cell RNA analysis of tumor and immune cells in asymptomatic and overt WM
4:19
A single-cell RNA analysis of tumor and immune cells in asymptomatic and overt WM
Romanos Sklavenitis-Pistofidis • 18 Oct 2024
Sub-typing Waldenström's macroglobulinemia: memory B-cell subtype and plasma cell-like subtype
1:51
Sub-typing Waldenström's macroglobulinemia: memory B-cell subtype and plasma cell-like subtype
Romanos Sklavenitis-Pistofidis • 18 Oct 2024

Related Videos

Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
2:19
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
Ashutosh Wechalekar • 9 Sep 2026
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
1:39
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
Elena Zamagni • 25 Sep 2026
Anselamimab in AL amyloidosis: combining and sequencing with plasma cell-directed treatment
2:14
Anselamimab in AL amyloidosis: combining and sequencing with plasma cell-directed treatment
Ashutosh Wechalekar • 9 Sep 2026
The content of VJHemOnc is intended for healthcare professionals